The study compared effectiveness of intranasal administration of glypin (human recombinant modified glucagon-like peptide-1) and reference drug Victoza in BALB/c mice. The minimum effective dose of intranasal glypin was 0.5 mg/kg, and a 2-fold elevation of this dose increased the parameters of glypin activity up to the maximal levels. During the first 2 h after intranasal administration, the effectiveness of glypin greatly surpassed that of Victoza. Duration of action and the time course of antihyperglycemic activity of intranasal glypin (1 mg/kg) matched to the best parameters attained during its subcutaneous application. A high effectiveness of intranasal glypin opens the vistas to its further examination and employment.

中文翻译：

---

鼻内人重组修饰的胰高血糖素样肽-1：在小鼠中具有高抗高血糖活性和作用持续时间

该研究比较了 glypin（人重组修饰的胰高血糖素样肽 1）和参考药物 Victoza 在 BALB/c 小鼠中鼻内给药的有效性。鼻内 glypin 的最小有效剂量为 0.5 mg/kg，该剂量的 2 倍升高可将 glypin 活性参数增加至最大水平。在鼻内给药后的前 2 小时内，glypin 的有效性大大超过了 Victoza。鼻内 glypin (1 mg/kg) 的作用持续时间和抗高血糖活性的时间过程与其皮下应用期间获得的最佳参数相匹配。鼻内 glypin 的高效性为其进一步检查和应用打开了前景。